

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Grazoprevir–elbasvir for treating chronic hepatitis C [ID842]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Merck Sharp & Dohme (grazoprevir–elbasvir) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addaction • Adfam • Addiction Today (Addiction Recovery Foundation) • African Health Policy Network • Black Health Agency • British Liver Trust • Compass UK • GMFA - The Gay Men’s Health Charity • Hemophilia Alliance • Hemophilia Society • HIV i Base • Liver4Life • Muslim Council of Britain • NAM Publications • National AIDS Trust • Positively UK • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust • The Hepatitis C Trust • UK Harm Reduction Alliance • UK Thalassaemia Society • YouthNet <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for Clinical Biochemistry and Laboratory Medicine • British Association for Sexual Health and HIV 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Drugs Action (Scotland) • Healthcare Improvement Scotland • Hospital Information Services – Jehovah’s Witnesses • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Blood and Transplant • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Scottish Viral Hepatology Group <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (ombitasvir/paritaprevir/ritonavir, dasabuvir) • Bristol-Myers Squibb Pharmaceuticals (daclatasvir) • Gilead Sciences (ledipasvir–sofosbuvir, sofosbuvir) • Janssen (simeprevir, telaprevir) • Meda Pharmaceuticals (ribavirin) • Merck Sharp & Dohme (boceprevir, peginterferon alfa 2b, ribavirin) • Mylan UK (ribavirin) • Roche Products (peginterferon alfa 2a,

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association for the Study of the Liver (BASL) • British Geriatrics Society • British HIV Association • British Infection Association • British Liver Nurses Forum • British Society of Gastroenterology • British Society of Haematology • British Transplantation Society • British Viral Hepatitis Group • HCV Action • Hemophilia Centre Doctors Association • Hemophilia Nurses Association • Hepatitis Nurse Specialist Forum • Infection Prevention Society • Medical Foundation for AIDS & Sexual Health • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for General Microbiology • United Kingdom Hemophilia Centre Doctors Association • UK Clinical Pharmacy Association • UK Clinical Virology Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Bradford City CCG • NHS Eastern Cheshire CCG • Welsh Government 	<p>ribavirin)</p> <ul style="list-style-type: none"> • Teva UK (ribavirin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Foundation for Liver Research • HCV Research UK • MRC Clinical Trials Unit • National Institute of Health Research • National Screening Committee • STOP-HCV UK • UCL Centre for Sexual Health & HIV Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations

from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: of the companies that markets comparator technologies; Healthcare Improvement Scotland;; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.